VEGFA and renal cell carcinoma: Finally, studies on bevacizumab (65, 66) showed that this VEGF-targeted agent could stimulate the maturation of DCs and decrease Tregs in clinical trials and reduce MDSCs in the tumor site in animal models of RCC (67).